Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (809)	12/24/1998 12:26:00 PM
From: Beltropolis Boy	Respond to of 1686

RESEARCH ALERT - EVEREN recommends buying Biogen CHICAGO, Dec 24 (Reuters) - EVEREN Securities said Thursday it viewed the sell-off in shares of Biogen Inc. <BGEN.O> as a buying opportunity and would be "aggressively" purchasing shares at current levels. Biogen shares fell sharply Wednesday after the surprise news that James Tobin would resign as chief executive officer. The stock closed at 79-13 on Nasdaq, down 7-1/16. It was down as much as 16-2/16 during the day. EVEREN says Biogen is a profitable biotechnology company that is marketing the leading treatment for multiple sclerosis, receives royalty revenues from four compounds, and has several promising products in clinical development. "We view investors as overreacting to the news, as it blindsided everybody on the street, and would be aggressively buying shares," EVEREN said in a report. It has the stock rated outperform on both an intermediate and long-term basis.

To: Vector1 who wrote (809)	12/24/1998 2:36:00 PM
From: MR. PANAMA (I am a PLAYER)	Respond to of 1686

Selling covered calls here may be a great idea to generate cash flow during a lull....

To: Vector1 who wrote (809)	12/28/1998 9:00:00 AM
From: Harold Engstrom	Read Replies (2) \| Respond to of 1686

The Vincent/Tobin things is bizarre. The problem probably stems from two very bright people with vision trying to run one company. Vincent started at the company when it was reportedly on the brink of failure and brought it from zero to a mini-pharm. It is probably difficult for him to someone else take the reins completely from him. Over the past few years, Biogen has put a very strong and professional management team together. They have built a strong organization primarily by promoting from within. And they have developed a methodology for bring a promising drug from the lab to market. In addition to the products that they already manufacture or license, VLA-4, anti-CD40L, LFA3TIP, and CVT124 are moving through the pipeline - and along with Avonex, some are being tried on multiple indications. In addition, Biogen said an IND for a new compound would be forthcoming in the not too distant future. Jim Tobin is an excellent CEO and he demonstrated that by helping to leave a very strong company behind him. I hope you are right about the company's earnings being so strong. With the relaunch of Avonex for 2ndary progressive slated for '00, Avonex momentum should continue. If the anti-CD40L data is good, then there will be a solid floor for the stock price. LFA3TIP should be the 1st new product out of the chute. Merck should be into Phase II VLA-4 trials by now. The clinical trials database shows Phase II Lupus trials for anti-CD40L began in November, but I haven't verified that. Thanks for your trading advice V1, Harold